Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recession continues to impact health care

This article was originally published in The Gray Sheet

Executive Summary

Medicaid expenditures grew at a faster pace than Medicare spending in 2009, at 9.9% and 8.1% respectively, according to CMS projections released Feb. 4. The jump in Medicaid spending was based largely on increased enrollment due to the recession, CMS said. Overall U.S. health care expenditures are expected to have grown 5.7% in 2009 to $2.5 trillion. The agency expects the recession contributed to lower demand for services with significant out-of-pocket expenses, and projects the growth in out-of-pocket spending slowed from 2.8% in 2008 to 2.1% in the U.S. in 2009. For the 10-year period from 2009-2019, CMS projects average annual spending growth overall will be 6.1% for hospitals and 5.9% for physician and clinical services. Last month, CMS reported that the growth of U.S. health care expenditures had slowed in 2008, the last full year for which data is available (1"The Gray Sheet" Jan. 11, 2010). CMS projects that by 2019, national health expenditures will reach $4.5 trillion, or 19.3% of the gross domestic product, with government health care spending growing at a faster rate than private spending

You may also be interested in...



Health Care Not Recession-Proof, National Spending Data Indicates

The current recession has had a more immediate impact on U.S. health care spending than seen in other recent economic downturns, according to the lead author of a Jan. 5 CMS report on 2008 national health expenditures

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel